Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, GlaxoSmithKline (GSK) has a market cap of $72.33 billion USD. According to our data, GlaxoSmithKline is ranked No.250 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $72.33 B |
4.82%
|
| Dec 31, 2024 | $69.00 B |
-5.14%
|
| Dec 29, 2023 | $72.74 B |
9.71%
|
| Dec 30, 2022 | $66.30 B |
-16.77%
|
| Dec 31, 2021 | $79.66 B |
26.76%
|
| Dec 31, 2020 | $62.84 B |
-17.72%
|
| Dec 31, 2019 | $76.37 B |
29.24%
|
| Dec 31, 2018 | $59.09 B |
13.79%
|
| Dec 29, 2017 | $51.93 B |
-2.98%
|
| Dec 30, 2016 | $53.53 B |
2.10%
|
| Dec 31, 2015 | $52.43 B |
-0.26%
|
| Dec 31, 2014 | $52.56 B |
-15.69%
|
| Dec 31, 2013 | $62.34 B |
28.92%
|
| Dec 31, 2012 | $48.36 B |
0.65%
|
| Dec 30, 2011 | $48.04 B |
22.60%
|
| Dec 31, 2010 | $39.19 B |
-2.12%
|
| Dec 31, 2009 | $40.04 B |
19.33%
|
| Dec 31, 2008 | $33.55 B |
-22.26%
|
| Dec 31, 2007 | $43.16 B |
-0.77%
|
| Dec 29, 2006 | $43.50 B |
7.94%
|
| Dec 30, 2005 | $40.30 B |
9.87%
|
| Dec 31, 2004 | $36.68 B |
5.61%
|
| Dec 31, 2003 | $34.73 B |
28.75%
|
| Dec 31, 2002 | $26.97 B |
-21.59%
|
| Dec 31, 2001 | $34.40 B |
-9.64%
|
| Dec 29, 2000 | $38.07 B |
4.16%
|
| Dec 31, 1999 | $36.55 B |
-17.93%
|
| Dec 31, 1998 | $44.53 B |
48.18%
|
| Dec 31, 1997 | $30.05 B |
55.86%
|
| Dec 31, 1996 | $19.28 B |
17.92%
|
| Dec 29, 1995 | $16.35 B |
45.30%
|
| Dec 30, 1994 | $11.25 B |
3.08%
|
| Dec 31, 1993 | $10.92 B |
-10.43%
|
| Dec 31, 1992 | $12.19 B |
-22.91%
|
| Dec 31, 1991 | $15.81 B |
98.94%
|
| Dec 31, 1990 | $7.95 B |
30.45%
|
| Dec 29, 1989 | $6.09 B |
38.71%
|
| Dec 30, 1988 | $4.39 B |
6.99%
|
| Dec 31, 1987 | $4.11 B |
20.98%
|
| Dec 31, 1986 | $3.39 B |
38.98%
|
| Dec 31, 1985 | $2.44 B |
75.25%
|
| Dec 31, 1984 | $1.39 B |
26.25%
|
| Dec 30, 1983 | $1.10 B |
-1.84%
|
| Dec 31, 1982 | $1.12 B |
158.73%
|
| Dec 31, 1981 | $0.43 B |
26.00%
|
| Dec 31, 1980 | $0.34 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Takeda Pharmaceutical
TAK
|
$45.76 B |
0.002 M
|
Japan
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
| Market Cap | = | GSK Stock Price | * | GSK Shares Outstanding |
| = | $35.68 | * | 2.03 B | |
| = | $72.33 B |